Printer Friendly

DISEASE DETECTION INTERNATIONAL, INC., WINS ARBITRATION BATTLE WITH EDITEK, INC. OVER VALUABLE PATENT RIGHTS

 IRVINE, Calif., Aug. 20 /PRNewswire/ -- Disease Detection International, Inc. (DDI) (NASD: OTC Bulletin Board: DDII), announced today that the company received notice from Judicial Arbitration and Mediation Services, Inc., that the arbitrator has issued tentative findings and an award in favor of Disease Detection International, Inc. against Editek, Inc. (EDI.EC), formerly Environmental Diagnostics, Inc. of Burlington, N.C. The arbitration findings relate to disputes between the companies dating back to 1988, involving Editek's wrongful termination of DDI's exclusive licensed rights to EDI's technology and patents.
 The judge's findings confirm that DDI holds the exclusive, worldwide, royalty free, rights to EDI's patents in the fields of infectious diseases in humans and veterinary diagnostics and for the detection of pregnancy and ovulation in humans. The judge also awarded DDI the right to recover its legal expenses from EDI. In addition, the findings also found the sub-license agreement between DDI and International Murex Corporation to be valid.
 In making the announcement, DDI's president and chief executive officer, H. Thad Morris, stated that "the findings were a complete and total victory for the company in retaining its rights to those patents which were threatened by EDI's wrongful attempt to terminate the license between the two companies.
 Mr. Morris further commented, "While the value of the EDI patents remain to be determined, EDI in press releases from August 1992 through October 1992, stated that the patents issued represent `extremely valuable' technology related to one-step immunoassays and due to the 1982 filing dates, may have a dominant position in the field of rapid diagnostic testing. This award retains these patent rights for DDI in the significant fields of use for infectious diseases and pregnancy tests."
 Disease Detection International, Inc. develops, manufactures and markets a variety of rapid, easy-to-use diagnostic tests in the field of infectious and sexually transmitted diseases in humans and veterinary practices. The company holds the patent used for its SeroCard(R) 7-minute, whole blood AIDS test now being marketed in South America. Trinity Biotech plc of Dublin, Ireland licensed and markets DDI's products in Europe and Asia. In addition, DDI and its 50-percent owned women's health care company, FHC Corporation, market a one-step pregnancy test in the professional, hospital, doctor's office and over- the-counter markets.
 -0- 8/20/93
 /CONTACT: H. Thad Morris, president and CEO of Disease Detection International, 714-457-1787/
 (DDII EDI)


CO: Disease Detection International, Inc.; Editek, Inc. ST: California, North Carolina IN: SU:

SM-PS -- NY007 -- 4620 08/20/93 09:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 20, 1993
Words:413
Previous Article:AMFED UNIT TO ACQUIRE YERINGTON DEPOSITS AND LOANS FROM PIONEER CITIZENS BANK
Next Article:ARROW REPORTS CORRECTION TO EARNINGS PER SHARE DATA AND APPOINTMENT OF SENIOR VICE PRESIDENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters